Lv5
1158 积分 2022-02-15 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
18天前
已完结
Systemic lupus erythematosus
2个月前
已完结
Advances in the treatment of systemic lupus erythematosus
2个月前
已完结
Optimization of CAR T-cell dose: a debated unresolved issue
3个月前
已完结
Novel strategies to manage CAR-T cell toxicity
3个月前
已完结
Designer lipids for delivering mRNA to the brain
3个月前
已完结
[China clinical practice guideline for stage Ⅳ primary lung cancer (2024 edition)]
4个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
5个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
7个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
7个月前
已完结
皖公网安备34019202002308
